Andrea Tan
Stock Analyst at Goldman Sachs
(2.08)
# 2,946
Out of 4,502 analysts
35
Total ratings
36.67%
Success rate
-1.13%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $74 → $102 | $74.50 | +36.91% | 6 | Jul 10, 2024 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $3.40 | +76.47% | 5 | Jul 1, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Neutral | $31 | $28.94 | +7.12% | 1 | Jun 5, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $4.05 | -50.62% | 3 | Jun 5, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $19 → $21 | $9.43 | +122.69% | 4 | Feb 29, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $19 → $30 | $28.24 | +6.23% | 2 | Feb 29, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $50 → $44 | $15.88 | +177.08% | 4 | Feb 27, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $3.22 | -37.89% | 1 | Dec 11, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $160 | $210.69 | -24.06% | 1 | Nov 20, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.10 | +674.19% | 2 | Aug 4, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $5.40 | -25.93% | 2 | Jan 9, 2023 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $178 → $375 | $283.46 | +32.29% | 1 | Dec 20, 2022 | |
| VERV Verve Therapeutics | Initiates: Sell | $13 | $7.48 | +73.80% | 1 | Dec 15, 2022 | |
| VOR Vor Biopharma | Maintains: Neutral | $6 → $4 | $0.95 | +320.34% | 2 | May 24, 2022 |
Insmed
Jul 10, 2024
Maintains: Buy
Price Target: $74 → $102
Current: $74.50
Upside: +36.91%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $3.40
Upside: +76.47%
Arrowhead Pharmaceuticals
Jun 5, 2024
Initiates: Neutral
Price Target: $31
Current: $28.94
Upside: +7.12%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $4.05
Upside: -50.62%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.43
Upside: +122.69%
Tarsus Pharmaceuticals
Feb 29, 2024
Maintains: Neutral
Price Target: $19 → $30
Current: $28.24
Upside: +6.23%
Day One Biopharmaceuticals
Feb 27, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $15.88
Upside: +177.08%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $3.22
Upside: -37.89%
Krystal Biotech
Nov 20, 2023
Initiates: Buy
Price Target: $160
Current: $210.69
Upside: -24.06%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.10
Upside: +674.19%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $5.40
Upside: -25.93%
Madrigal Pharmaceuticals
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $283.46
Upside: +32.29%
Verve Therapeutics
Dec 15, 2022
Initiates: Sell
Price Target: $13
Current: $7.48
Upside: +73.80%
Vor Biopharma
May 24, 2022
Maintains: Neutral
Price Target: $6 → $4
Current: $0.95
Upside: +320.34%